Free Trial Information
BioCentury | Dec 31, 2020
Distillery Therapeutics

T cell-specific targeting of KCNA3 for lupus nephritis

...T cells. In patient-derived memory T cells, the nanoparticles reduced the percentage of cells expressing CD40L...
...peripheral blood mononuclear cells (PBMCs), pretreatment of the PBMCs with the nanoparticles reduced levels of CD40L...
...syndrome.TARGET/MARKER/PATHWAY: Potassium channel Kv1.3 (KCNA3); protein tyrosine phosphatase receptor type C (PTPRC; CD45; CD45R); CD40 ligand (CD40L; CD40LG; CD154); interferon γ...
Read More
BioCentury | Dec 15, 2020
Finance

Dec. 14 Quick Takes: Locanabio raises $100M series B; plus rare bleeding disorder newco Hemab, raises for Rani, CG, InnoSkel, Denovo, Biosion and more

Vida leads Locanabio’s $100M B roundLocanabio Inc. raised $100 million in a series B financing led by Vida Ventures, with participation from new investors RA Capital, Invus, Acuta Capital and SVB Leerink as well as existing...
Read More
BioCentury | Oct 9, 2020
Finance

Kronos’ post-IPO gains build on $1B+ postmoney valuation

...from the company’s most advanced program, dual SIRPA/CD40L-targeting...
...to non-alcoholic steatohepatitis and myelofibrosis.  TARGETSCD40L (CD40LG; CD154...
Read More
BioCentury | Jul 15, 2020
Product Development

University of Queensland COVID-19 vaccine becomes seventh with CEPI funding to enter the clinic

...collaboration with Kansas State University. The live attenuated replicating viral vector vaccine, dubbed TNX-2300, expresses CD40L...
...is partnered with Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKEX:2196). Targets CD40L (CD40LG; CD154) - CD40 ligand Sandi...
Read More
BioCentury | Jun 19, 2020
Deals

In second innovative deal this month, AbbVie gains option to Alpine’s ‘first-in-class’ lupus program

...response vs. placebo in a Phase IIb SLE trial. The compound blocks the co-stimulatory receptor CD40L...
...cells and B cells. Durand said that while Alpine has not directly compared ALPN-101 to CD40/CD40L...
Read More
BioCentury | Jun 16, 2020
Finance

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

...are based on the biotech’s TriMix technology, which combines therapeutic mRNA molecules that encode CD70, CD40L...
...of the deal and financial terms were still being finalized. Targets CD40L (CD40LG; CD154) - CD40 ligand...
Read More
BioCentury | May 29, 2020
Finance

May 28 Quick Takes: Illumina leads $70M Ginkgo round; plus Arena, Viela Bio, BioCryst, Progenity and Microbion

...undisclosed. The candidate has Orphan Drug and Fast Track designations. Targets CD40L (CD40LG; CD154) - CD40 ligand...
Read More
BioCentury | Mar 25, 2020
Finance

March 24 Quick Takes: Apexigen brings series C to $123M; plus Nanjing F&S, FCA and Asieris

Apexigen boosts series C with $65M extension Apexigen Inc. added $65 million to its 2018 series C, bringing the round to $123 million. The extension was led by Decheng Capital and new investor Oceanpine Capital,...
Read More
BioCentury | Mar 7, 2020
Emerging Company Profile

Kira: depleting activated dendritic cells

First-in-class mAbs against activated dendritic cells from Australian newco Kira could block the inflammation and immune response associated with GvHD and autoimmune diseases without the risk of infection that accompanies broad immunosuppression. Founding CEO Dan...
Read More
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

A comparison of therapies that have shown promise, or failed to do so, in myasthenia gravis suggests targeting production of autoantibodies may be a less fruitful approach than blocking the effects of the autoantibodies or...
Read More
Items per page:
1 - 10 of 334